Abstract
the majority of patients with ovarian cancer are generally diagnosed with advanced-stage disease. Despite the advances in chemotherapy, most patients have a poor prognosis due to difficulties in diagnosing the disease. tumor cells often overexpress specific proteins; as a result, tumor-reactive antibodies can be observed in the circulation of patients soon after initial tumor development and before circulating antigens are detected. taylor and colleagues assessed autoantibody responses in patients with benign and malignant ovarian lesions—”assessment of this autoantibody response against specific proteins can provide a cancer screening tool superior to those currently available” state the researchers. tumor-reactive igG has been detected in various tumors, including ovarian cancer. moreover, tumor-reactive igG can be identified early in tumor development and has been associated with tumor progression. the researchers used a Screening
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
